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Several pharmaceutical and biotechnology companies are
actively pursuing the clinical development of inhibitors of the
serine/threonine kinase mammalian target of rapamycin (mTOR)
for cancer. Rapamycin, the original natural product compound
first shown to inhibit mTOR, is already an approved drug for pre-
vention of allograft rejection in recipients of organ transplants
due to its potent inhibition of T cell activation. What is the logic
behind the use of the same agent for cancer indications? This
focus will review the background supporting the potential utility
of mTOR inhibitors as anticancer agents, then compare and
contrast two different approaches for its clinical development.
The first approach is empiric, based on the traditional phase I
design of escalation to maximum tolerated dose in a broad
patient population, followed by larger trials focused on those
tumor types that demonstrate hints of activity in the phase I set-
ting. The second approach is mechanism based, building on
knowledge of signaling pathways that activate mTOR, where
the dose is selected by measuring target enzyme inhibition in
tumor cells and patient eligibility is defined by molecular profil-
ing studies. I will speculate on potential outcomes from both
approaches as well as my view of the eventual role that mTOR
inhibitors may play in the cancer drug armamentarium.
mTOR: A central regulator of cell growth
Rapamycin, a bacterially derived natural product, induces G1
arrest in various cell types at low nanomolar concentrations.
The mechanism was cleverly deciphered through yeast genetic
screens that identified a serine/threonine kinase named target
of rapamycin (TOR) (Heitman et al., 1991), which is a member
of the larger phosphatidylinositol 3-kinase (PI3K) related family
that includes PI3K, ATM, and ATR. Rapamycin exerts its action
by first binding to the immunophilin FK506 binding protein
(FKBP12). The FKBP12/rapamycin complex then binds mTOR,
preventing phosphorylation of downstream targets such as S6
kinase (S6K) and 4EBP1 (see Abraham, 2002; Schmelzle and
Hall, 2000; Shamji et al., 2003).
mTOR receives a diverse set of signaling inputs. Among the
most relevant for a discussion of cancer is mTOR activation by
growth factors like IGF-1, which activates the PI3K/Akt signaling
pathway. Akt directly phosphorylates a number of proteins that
impact cell survival and proliferation (reviewed in Vivanco and
Sawyers, 2002), but the details defining the connection to
mTOR were unclear until recently. Now a series of biochemical
and genetic studies have established a pathway from Akt to
mTOR involving the tuberous sclerosis complex proteins tuberin
and hamartin, as well as the small Ras-like GTPase Rheb.
Tuberous sclerosis complex 2 (TSC2) is a direct substrate of Akt
(Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002)
(Figure 1). Unphosphorylated TSC2 is bound to TSC1 in a com-
plex that blocks mTOR activation. Akt-mediated phosphory-
lation of TSC2 disrupts the TSC1/TSC2 complex, allowing
unrestrained mTOR kinase activity. Rheb (Ras homolog
enriched in brain) functions in this pathway downstream of
TSC2 and upstream of mTOR (Garami et al., 2003; Saucedo et
al., 2003; Stocker et al., 2003; Zhang et al., 2003). Interestingly,
Rheb is highly expressed in transformed cancer cell lines and
functions as an oncogene in fibroblast transformation models,
but can also block transformation by Ras or B-Raf (Clark et al.,
1997; Im et al., 2002).
A simple linear model of this pathway (Akt-TSC1/2-Rheb-
TOR-S6K) cannot account for all experimental findings. For
example, PI3K can activate S6K independently of Akt 
and mTOR through an alternative pathway involving PDK1
(Radimerski et al., 2002). In addition, mTOR functions in a nutri-
ent sensor pathway independent of PI3K and Akt. mTOR is
inhibited during conditions of nutrient deprivation, which leads
to a slowdown in cell growth (defined as cell size or mass as
opposed to cell proliferation). This starvation response makes
teleological sense because mTOR plays a key regulatory role in
protein translation through modulation of S6K and 4EBP1
action. The recently isolated mTOR binding protein Raptor pro-
vides a potential mechanism for how mTOR regulates down-
stream effectors (Hara et al., 2002; Kim et al., 2002). Because
Raptor can also bind S6K and 4EBP1, it may function as a scaf-
fold, keeping this signaling complex primed for rapid response
to inputs from various pathways.
Because S6K and 4EBP1 play crucial roles in regulating
translation, there has been much interest in defining the down-
stream mRNA targets of mTOR. The 5′ untranslated regions of
cyclin D1 and c-Myc mRNAs both have CAP sequences, ren-
dering them subject to regulation by 4EBP1. Cyclin D1 and c-
Myc are regulated in part by mTOR since the levels of both
proteins can fall in cells exposed to rapamycin in certain con-
texts (Hosoi et al., 1998; Muise-Helmericks et al., 1998; Takuwa
et al., 1999). Global transcriptome analyses using polysome
fractions are beginning to define the range of mTOR-regulated
mRNAs (Peng et al., 2002; Rajasekhar et al., 2003; Shamji et
al., 2000). At a first approximation, these analyses appear to
confirm important functional roles of c-Myc and cyclin D1 in
rapamycin-induced growth arrest (Gera et al., 2003).
Rapamycin has anticancer activity
The natural products program at the National Cancer Institute
identified rapamycin as a potential anticancer agent in the
1970s (Douros and Suffness, 1981). Once the biochemical TOR
was identified and more detailed activity profiles against a panel
of human tumor cell lines were completed, some very interest-
ing patterns emerged. Specifically, cell lines derived from differ-
ent cancer types were noted to undergo G1 arrest when
exposed to 1 nM rapamycin, a concentration which closely
matches that required for biochemical inhibition of mTOR in
cells. Notably, several other tumor cell lines that failed to
respond to the 1 nM dose did undergo growth arrest at significantly
higher concentrations (?1000 nM). While these phenotypic
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screening studies revealed the broad potential for rapamycin as
an antiproliferative agent, they did not uncover the mechanism.
Nonetheless, the results define two groups of rapamycin-sensi-
tive cell lines—those whose response correlates with inhibition
of mTOR (1 nM) (group 1) and those that require significantly
higher concentrations (group 2). Of note, the failure of the group
2 cell lines to respond to low “dose” (1 nM) rapamycin cannot be
explained by insufficient blockade of mTOR kinase activity
because 1 nM rapamycin was equally effective at inhibiting S6K
and 4EBP1 phosphorylation in both groups (Neshat et al.,
2001). These data support the notion that mTOR is the biologi-
cally relevant target of rapamycin for the tumor lines in group 1,
whereas other targets are relevant in group 2.
Initial clinical development of mTOR inhibitors—The
empiric strategy
In the absence of any histologic subtype or molecular marker
that can distinguish between group 1, group 2, and nonrespon-
sive cell lines, the initial clinical development of mTOR inhibitors
in cancer has proceeded empirically. Several pharmaceutical
companies have compounds in clinical trials for this indication.
Among the most advanced is CCI-779 from Wyeth. CCI-779 is
an ester of rapamycin with comparable potency and specificity
for mTOR but with a longer half-life. Phase I and phase II clinical
trials of the intravenous formulation have been completed and
show promising enough results to warrant a phase III random-
ized trial that is underway. A brief review of the rationale and
clinical details underlying this empiric approach is warranted to
contrast with the molecularly driven approach described sub-
sequently (see Dancey, 2002 for a comprehensive review of the
clinical experience with mTOR inhibitors in cancer).
Following the traditional strategy of defining the maximum
tolerated dose (MTD), Wyeth has conducted two phase I dose
escalation studies of CCI-779 in patients with solid tumors using
two different delivery schedules—weekly versus daily for 5 days
every 2 weeks (Hidalgo et al., 2000; Raymond et al., 2000).
Toxicities such as low platelet counts and fatigue were observed
at high doses, but the drug was generally well tolerated.
Importantly, the doses tested in these cancer trials gave peak
plasma concentrations well above that required for inhibition of
mTOR, but the intermittent nature of the dosing allowed troughs
to fall below mTOR inhibition levels. Clinical responses were
observed in several patients with advanced stage kidney can-
cer; therefore, a phase II trial was conducted in this disease.
Using three different doses of CCI-779 given weekly, the objec-
tive response rate was only 5%, but there was a higher rate of
minor responses (29%) and stable disease (40%) (Atkin et al.,
2002). Of note, responses were observed equally across all
doses (all of which give peak serum levels that block mTOR).
On this basis, a phase III randomized trial has been initiated.
Deconvoluting the mechanism of response in kidney
cancer
Now that the empiric clinical development plan of CCI-779 has
identified renal cell carcinoma as a potential mTOR-dependent
cancer, it is interesting to speculate on possible mechanisms.
Two scenarios come to mind based on the critical role of angio-
genesis in these tumors due to expression of hypoxia inducible
factor (HIF) (reviewed in (Kaelin, 2002). The first is based on
recent evidence that mTOR inhibitors may be antiangiogenic
agents. PI3K, Akt, and mTOR are all critical for vascular
endothelial growth factor (VEGF)-mediated endothelial cell pro-
liferation, survival, and migration (Yu and Sato, 1999). In fact,
rapamycin-coated coronary artery stents prevent restenosis in
patients with coronary artery disease who undergo angioplasty
(Morice et al., 2002). Preclinical studies suggest that this effect
of mTOR inhibitors on endothelial growth may also apply to
tumor angiogenesis since rapamycin blocked the in vivo growth
of tumor cells that were resistant to rapamycin in vitro (Guba et
al., 2002). A recent antiangiogenesis trial in kidney cancer (not
involving an mTOR inhibitor) demonstrated that anti-VEGF anti-
body was not effective in causing tumors to shrink but caused
significant delays in the time to tumor progression (Yang et al.,
2003). This clinical outcome is strikingly reminiscent of the
phase II results of CCI-779 in kidney cancer and begs the ques-
tion of whether mTOR inhibitors may work by this mechanism.
A second scenario to explain the activity of CCI-779 in kid-
ney cancer is based on evidence that mTOR can regulate HIF
expression through the PI3K/Akt pathway (Hudson et al., 2002;
Zhong et al., 2000). Therefore, mTOR inhibitors could have
direct effects on tumor cells by reducing HIF levels as well as
indirect effects on the endothelial cells recruited for tumor
angiogenesis.
Rethinking the empiric clinical development strategy for
mTOR inhibitors
The usual justification for pursuing an empiric drug develop-
ment approach is that the molecular target of the drug is
unknown or its disease-specific role is poorly understood. As a
result, drug dose is chosen on the basis of what can be tolerat-
ed without inordinate toxicity. In this way, it is assumed that any
clinical activity will not be missed due to insufficient drug levels.
Once dose-limiting side effects are observed, the schedule of
drug delivery is typically modified to allow recovery from any
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Figure 1. Signaling pathways involving mTOR
The diagram depicts the current view of mTOR regulation through the
PI3K/Akt pathway based on biochemical and genetic studies. See text for
more details.
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toxicities. Hence, an intermittent regimen using doses just
below the toxic level is the typical outcome of phase I evalua-
tions of novel agents. Based on this approach, the early phase
CCI-779 studies converged on a weekly dosing regimen.
However, mTOR inhibitors represent an unusual example
because of the broad clinical experience with rapamycin as an
immunosuppressive agent for patients receiving organ trans-
plants. For this indication, the dose is based on that required to
inhibit T cell activation, which correlates with mTOR inhibition in
blood cells.These patients take rapamycin daily at relatively low
doses (in comparison to the weekly “cancer” dose of CCI-779)
with minimal side effects. A recent phase I clinical report of a
second mTOR inhibitor, RAD-001 (Novartis), measured S6K in
blood cells to guide dose selection in cancer patients
(O’Donnell et al., 2003).
If mTOR is the relevant target in cancer cells, why wasn’t
this low dose, daily schedule evaluated initially? And why not
select patients whose tumors are more likely to be mTOR
dependent? Obviously, the details underlying the decision-
making processes at pharmaceutical companies are not public
knowledge, but I will speculate on a few potential reasons. First,
a daily dosing schedule would lead to constitutive T cell sup-
pression, a side effect that one would prefer not to have in can-
cer patients. My personal view is that immune suppression is of
secondary concern in the initial stages of developing an anti-
cancer agent and should be factored into decision making only
after the primary goal of tumor response has been achieved.
Second, in vitro studies have defined a second population of
rapamycin-sensitive tumor cell lines (group 2, see above) where
the relevant target of drug action is not mTOR (perhaps another
PIKK family kinase?). In hopes of capturing this second group of
tumors, one would not want to restrict clinical evaluation to daily,
low dose mTOR inhibitor because this would only be effective
against those tumors presumed to be mTOR dependent (group
1). Third, it would be difficult to convince upper management to
support a clinical development program focused exclusively on
mTOR-dependent cancers without any knowledge of the size of
the target population or the tools to identify the patients. Finally,
marketing departments would presumably be concerned about
the confusion generated by parallel use of the same drug for
immune suppression and cancer. Reformulation into a new
compound with a different schedule of administration could
address this issue (albeit, cosmetically). I reiterate that my com-
ments in this paragraph are highly speculative, but I hope that
they help illustrate the complex set of scientific, economic, and
regulatory considerations that influence decisions underlying a
clinical development path.
An alternative clinical development strategy using
molecularly selected patients
Studies of kinase inhibitors such as imatinib (also called
Gleevec or STI571) indicate that these drugs can have tremen-
dous clinical activity in appropriately selected patients. This
experience has led to the notion that certain cancers are kinase
dependent, typically due to fusions, point mutations, or amplifi-
cation affecting the kinase gene that is targeted by the inhibitor
(reviewed in Sawyers, 2003). In general, these genetic events
enhance enzymatic activity of the kinase and serve as onco-
genic events driving the growth of the cancer. Since mTOR is a
kinase, can a similar paradigm of clinical development be
applied here?
Strict application of the imatinib paradigm is unlikely since
there is currently no evidence that the mTOR gene is mutated or
amplified in human cancer. However, preclinical observations
suggest that tumors with primary genetic abnormalities affect-
ing pathways that regulate mTOR are, in fact, dependent on
mTOR. These abnormalities include upregulation of the
PI3K/Akt pathway, directly or by loss of the tumor suppressor
phosphatase PTEN, as well as mTOR upregulation by TSC2
loss. PTEN null tumors are sensitive to mTOR inhibitors in sev-
eral different human and murine preclinical models (Grunwald
et al., 2002; Neshat et al., 2001; Podsypanina et al., 2001; Shi et
al., 2002). Transformation induced by oncogenic alleles of Akt,
but not Myc or Ras, is also reversed by mTOR inhibition (Aoki et
al., 2001). Recent studies in conditional PTEN knockout or
transgenic Akt mouse models confirm a role for mTOR in either
aberrant cell growth (Kwon et al., 2003) or transformation
through the PI3K/Akt pathway (E. Holland, personal communi-
cation; W. Sellers, personal communication). Similarly, tumors
caused by loss of TSC2 also show enhanced sensitivity to
rapamycin in growth assays (Kenerson et al., 2002).
The mTOR dependency of these tumors, whether induced
by loss of PTEN or TSC2 or by activation of PI3K or Akt, shares
conceptual similarity to synthetic lethal relationships originally
described in yeast. Loss of PTEN or TSC2 seems to render
mTOR essential in tumor cells but not in surrounding normal
cells. However, genetic studies in worms and flies make it clear
that TOR is essential for normal development (Long et al., 2002;
Oldham et al., 2000; Zhang et al., 2000). Because TOR is highly
conserved, it is likely that certain normal mammalian functions,
including T cell function, will be mTOR dependent. Nonetheless,
the clinical experience with rapamycin as an immuno-
suppressive agent indicates that mTOR inhibitors are
well tolerated.
An alternative group of tumors that might also be mTOR
dependent are those that express high levels of mTOR-regulat-
ed mRNAs, such as cyclin D1 or Myc. Because both genes are
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Table 1. Potential mTOR-dependent cancers
Molecular lesion Clinical disease
Upstream of mTOR
PTEN loss Glioblastoma
Prostate cancer
Endometrial cancer
Othersa
PI3K/Akt activation Breast cancer (Her2+)
Chronic myeloid leukemia (Bcr-Abl)
Ovarian cancer 
(PI3K or Akt gene amplification)
Othersa
TSC1/2 loss Tuberous sclerosis
Downstream of mTOR
cyclin D1 overexpression Mantle cell lymphoma
Breast cancer
Myc overexpression Burkitts lymphoma
Other Myc-driven cancers?
HIF overexpression Kidney cancer
Others?
aFor more complete listings, see Vivanco and Sawyers, 2002.
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also regulated by mTOR-independent mechanisms, it is difficult
to anticipate how effective an mTOR inhibitor might be in reduc-
ing the expression of either protein. This, as well as the mTOR
dependency of PTEN or TSC2-deficient cancers, can be tested
in clinical trials where patient selection is based on document-
ing the relevant molecular pathway abnormality in tumor tissue.
The greatest challenge in designing these clinical trials is
identification of molecularly defined patient cohorts (Table 1).
Traditional inclusion criteria using tumor histology and site of
origin will fail miserably because the molecular phenotype can-
not be discerned from the clinical phenotype (tuberous sclerosis
may be an exception).The most appropriate tools for discerning
these phenotypes in the context of a clinical trial have not been
defined. Among the potential approaches are proteomic or gene
expression profiling to recognize signatures of kinase depen-
dency. A first iteration of this approach, through the use of
phospho-specific antibodies against specific kinase targets or
substrates, shows promise in initial immunohistochemical appli-
cations (Choe et al., 2003). Limitations include the tricky perfor-
mance characteristics of certain antibodies and the potential
need for large numbers of optimized antibodies for comprehen-
sive evaluation. It may also be possible to recognize kinase acti-
vation through gene expression profiling (Allander et al., 2001;
Shai et al., 2003). Tissue availability and tumor heterogeneity
present additional obstacles. Nonetheless, several of these
approaches are under evaluation in small clinical studies of
mTOR inhibitors. One possibility is that pilot trials will identify
biomarkers that can be incorporated more easily into large
scale studies.
Expectations
mTOR inhibitors are now far along on the clinical development
path as anticancer agents, but it remains unclear how the story
will unfold. The empiric approach has uncovered a low but
reproducible objective response rate in kidney cancer patients.
There is the impression of a much larger rate of disease stabi-
lization, but this must be confirmed by a randomized trial. mTOR
inhibitors will also be combined empirically with other agents
(like interferon in kidney cancer) in an effort to increase the
response rate, but these trials will be conducted without molec-
ular insight into the mechanism of response. Although we all
hope for success, this strategy is strikingly similar to recent
combination trials of EGFR inhibitors with chemotherapy in
advanced stage lung cancer (reviewed in Dancey and Freidlin,
2003). Single agent response rates with EGFR inhibitors in
these patients are low but reproducible; the molecular basis of
response is unknown; and four large randomized trials of EGFR
inhibitors plus chemotherapy were all negative.
The alternative approach of using molecular insights from
preclinical work to select patients is just now being evaluated.
Efforts to identify appropriate patients based on immunohisto-
chemical staining of tumor biopsies have been convincing
enough to launch exploratory trials, but the robustness of these
assays in realtime clinical settings remains to be defined.
If we assume that these assays are accurate and that con-
tinuous daily dosing of mTOR inhibitors effectively blocks mTOR
in tumor cells, what clinical outcomes might we expect? There
are several issues to consider. First, mTOR inhibition in sensi-
tive tumor cell lines typically causes G1 arrest rather than apop-
tosis. Therefore, objective response rates may be low but
disease stabilization could be high. Second, even though we
have the tools to recognize tumors with loss of PTEN or activa-
tion of Akt, we do not know if this molecular abnormality repre-
sents an early or late event in the history of that tumor. This
issue could be critical because an inhibitor that blocks an initiat-
ing oncogenic event is, presumably, more likely to induce a clin-
ical response than one that blocks a later event involved in
disease progression.
No matter the outcome, it is likely that combination therapy
will be required to fully evaluate the potential of mTOR inhibitors
in order to maximize response rates and prevent drug resis-
tance. To avoid mistakes of the past, we need to select combi-
nations based on mechanistic insights into why certain patients
respond and others do not. One possibility is an mTOR plus
EGFR inhibitor combination, particularly in a disease like
glioblastoma where PTEN loss and genome-based EGFR acti-
vation can occur in the same tumor (Choe et al., 2003).
Furthermore, perturbations in one signaling pathway may alter
the cellular response to inhibition of another, as has been
observed with PTEN and EGFR in laboratory models (Bianco et
al., 2003; She et al., 2003). The good news is that we finally
have a very nice selection of signaling pathway inhibitors, and
we have the tools to select the patients. We just have to get to
work and do the right clinical experiments.
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